| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 0450 |
Emergency room services |
99,287 |
84,593 |
$5.36M |
| 99199 |
Unlisted special service, procedure or report |
59,010 |
48,969 |
$3.08M |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
13,274 |
12,960 |
$2.19M |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
21,908 |
20,529 |
$1.80M |
| 70450 |
Computed tomography, head or brain; without contrast material |
17,093 |
16,459 |
$1.74M |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
21,615 |
18,756 |
$1.67M |
| 80053 |
Comprehensive metabolic panel |
131,828 |
107,226 |
$1.36M |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
48,832 |
43,943 |
$1.17M |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
161,715 |
128,031 |
$916K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
35,554 |
8,515 |
$892K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
5,266 |
5,205 |
$870K |
| Z7502 |
|
23,083 |
22,300 |
$870K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
17,283 |
16,557 |
$852K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
12,300 |
10,972 |
$805K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
13,058 |
12,113 |
$741K |
| 76700 |
Ultrasound, abdominal, real time with image documentation; complete |
10,411 |
10,216 |
$735K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
11,229 |
9,604 |
$700K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
26,158 |
23,092 |
$663K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
3,988 |
3,925 |
$648K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
6,430 |
6,265 |
$637K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
4,165 |
4,032 |
$636K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
17,238 |
5,428 |
$587K |
| 97112 |
Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination |
23,682 |
6,306 |
$544K |
| 71045 |
Radiologic examination, chest; single view |
54,353 |
44,930 |
$531K |
| 71046 |
Radiologic examination, chest; 2 views |
25,398 |
24,708 |
$501K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
22,422 |
6,282 |
$482K |
| 71260 |
Computed tomography, thorax, diagnostic; with contrast material |
2,367 |
2,335 |
$457K |
| 83880 |
|
20,671 |
18,094 |
$395K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
10,156 |
8,603 |
$386K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
5,445 |
5,336 |
$340K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
15,013 |
13,987 |
$333K |
| 78452 |
Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress |
1,486 |
1,367 |
$333K |
| J3490 |
Unclassified drugs |
23,265 |
11,034 |
$326K |
| 84484 |
|
38,399 |
32,408 |
$325K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
4,497 |
3,727 |
$312K |
| 97750 |
|
5,404 |
3,665 |
$308K |
| 76815 |
Ultrasound, pregnant uterus, real time with image documentation, limited |
5,407 |
4,094 |
$296K |
| 83690 |
|
40,430 |
36,857 |
$291K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
9,306 |
8,882 |
$285K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
2,936 |
2,074 |
$284K |
| 76830 |
Ultrasound, transvaginal |
4,504 |
4,393 |
$282K |
| 0250 |
|
12,907 |
6,793 |
$269K |
| 84443 |
Thyroid stimulating hormone (TSH) |
21,043 |
19,525 |
$263K |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
5,539 |
5,021 |
$259K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
5,079 |
4,838 |
$256K |
| S0119 |
Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) |
8,259 |
7,762 |
$252K |
| 0270 |
|
22,556 |
10,063 |
$245K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
32,839 |
25,952 |
$245K |
| 59025 |
Fetal non-stress test |
8,222 |
2,835 |
$234K |
| 76805 |
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation |
2,785 |
2,651 |
$230K |
| 70486 |
|
1,209 |
1,198 |
$225K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
3,807 |
3,534 |
$224K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
7,920 |
7,049 |
$220K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
4,158 |
3,922 |
$209K |
| 93971 |
|
2,303 |
2,273 |
$204K |
| 76801 |
|
3,775 |
3,143 |
$204K |
| Z9725 |
|
4,659 |
4,231 |
$200K |
| A9502 |
Technetium tc-99m tetrofosmin, diagnostic, per study dose |
1,501 |
1,391 |
$174K |
| 97139 |
|
9,126 |
1,955 |
$168K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
2,354 |
2,289 |
$163K |
| 81001 |
|
56,745 |
52,157 |
$159K |
| 76817 |
Ultrasound, pregnant uterus, real time with image documentation, transvaginal |
2,860 |
2,448 |
$154K |
| 71250 |
|
1,460 |
1,421 |
$153K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
5,323 |
5,185 |
$148K |
| 73610 |
|
6,058 |
5,773 |
$147K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
5,492 |
5,348 |
$147K |
| 73630 |
|
7,222 |
6,796 |
$145K |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
994 |
979 |
$144K |
| 78815 |
Positron emission tomography (PET) for limited area imaging |
314 |
279 |
$144K |
| 76770 |
|
1,979 |
1,947 |
$140K |
| 80143 |
|
4,713 |
4,142 |
$140K |
| 93017 |
|
2,585 |
2,418 |
$139K |
| 99291 |
Critical care, evaluation and management of the critically ill patient, first 30-74 minutes |
1,846 |
1,148 |
$139K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
25,578 |
23,783 |
$138K |
| 73030 |
|
5,279 |
5,090 |
$127K |
| 0762 |
|
891 |
304 |
$126K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
9,233 |
9,023 |
$115K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
5,297 |
4,612 |
$114K |
| 73130 |
|
4,245 |
4,070 |
$111K |
| 88307 |
|
1,487 |
1,436 |
$110K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
18,132 |
16,554 |
$106K |
| 73721 |
Magnetic resonance imaging, any joint of lower extremity; without contrast material |
304 |
294 |
$106K |
| 73562 |
|
4,828 |
4,563 |
$106K |
| 87040 |
|
11,081 |
8,967 |
$105K |
| 72131 |
|
539 |
537 |
$104K |
| 93970 |
|
962 |
925 |
$103K |
| L8699 |
Prosthetic implant, not otherwise specified |
13 |
13 |
$103K |
| 80179 |
|
4,615 |
4,083 |
$102K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
3,845 |
3,139 |
$98K |
| 73110 |
|
3,870 |
3,678 |
$95K |
| 82805 |
|
6,537 |
5,235 |
$95K |
| 80061 |
Lipid panel |
10,292 |
10,022 |
$89K |
| 90715 |
|
2,211 |
2,201 |
$89K |
| T1999 |
Miscellaneous therapeutic items and supplies, retail purchases, not otherwise classified; identify product in "remarks" |
14,311 |
7,022 |
$86K |
| J2785 |
Injection, regadenoson, 0.1 mg |
514 |
433 |
$86K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
11,494 |
9,930 |
$84K |
| 83605 |
|
12,316 |
9,623 |
$83K |
| 80076 |
|
9,240 |
8,582 |
$80K |
| 99070 |
|
56,519 |
28,502 |
$79K |
| 82962 |
|
10,597 |
5,781 |
$76K |
| 0637 |
|
10,443 |
5,246 |
$71K |
| 73502 |
|
1,884 |
1,822 |
$66K |
| 96367 |
|
1,701 |
1,066 |
$66K |
| 76819 |
Fetal biophysical profile; without non-stress testing |
1,685 |
1,426 |
$63K |
| 73080 |
|
1,940 |
1,869 |
$62K |
| 72148 |
Magnetic resonance imaging, lumbar spine; without contrast material |
161 |
161 |
$61K |
| 0510 |
|
1,994 |
1,585 |
$60K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
3,805 |
3,773 |
$60K |
| 97116 |
|
3,508 |
1,423 |
$59K |
| 83735 |
|
24,390 |
9,632 |
$58K |
| 84702 |
|
5,917 |
4,868 |
$56K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
1,040 |
1,011 |
$55K |
| 86900 |
|
8,716 |
7,985 |
$54K |
| 82803 |
|
3,500 |
2,446 |
$53K |
| 0729 |
|
1,419 |
1,155 |
$52K |
| 81003 |
|
20,989 |
19,599 |
$52K |
| 86850 |
|
5,392 |
4,894 |
$52K |
| 76870 |
|
906 |
874 |
$51K |
| 72100 |
|
1,653 |
1,640 |
$50K |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
1,994 |
1,121 |
$50K |
| 36415 |
Collection of venous blood by venipuncture |
26,220 |
23,453 |
$49K |
| 72110 |
|
986 |
978 |
$48K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
8,068 |
7,888 |
$46K |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
5,303 |
4,458 |
$46K |
| 73590 |
|
1,714 |
1,634 |
$44K |
| 84132 |
|
1,660 |
1,588 |
$43K |
| 86901 |
|
9,710 |
8,905 |
$43K |
| 70553 |
Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences |
73 |
73 |
$43K |
| 0360 |
|
306 |
204 |
$42K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
7,630 |
6,542 |
$41K |
| 81025 |
|
6,042 |
5,767 |
$41K |
| G0378 |
Hospital observation service, per hour |
1,132 |
889 |
$39K |
| 82330 |
|
5,812 |
4,376 |
$39K |
| 85610 |
|
14,771 |
12,166 |
$37K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
5,203 |
4,925 |
$37K |
| 87641 |
|
3,327 |
3,123 |
$36K |
| 0761 |
|
1,162 |
891 |
$36K |
| 01967 |
Neuraxial labor analgesia/anesthesia for planned vaginal delivery |
113 |
110 |
$36K |
| 73090 |
|
1,484 |
1,405 |
$35K |
| Z7610 |
|
10,436 |
5,007 |
$34K |
| 93880 |
|
330 |
329 |
$34K |
| 85027 |
|
9,201 |
6,861 |
$34K |
| 74018 |
|
2,079 |
1,870 |
$33K |
| 70491 |
|
146 |
142 |
$32K |
| 85730 |
|
7,343 |
6,528 |
$32K |
| 73564 |
|
936 |
909 |
$31K |
| 88304 |
|
1,792 |
1,649 |
$31K |
| 99233 |
Prolong inpt eval add15 m |
1,127 |
404 |
$31K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
5,073 |
4,332 |
$30K |
| C1776 |
Joint device (implantable) |
15 |
15 |
$29K |
| 84703 |
|
12,502 |
11,549 |
$29K |
| 76536 |
|
420 |
417 |
$28K |
| 72040 |
|
989 |
981 |
$28K |
| 87186 |
|
6,183 |
5,924 |
$28K |
| 93226 |
|
525 |
510 |
$27K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
287 |
271 |
$27K |
| 84145 |
|
2,933 |
2,306 |
$25K |
| 87077 |
|
5,779 |
5,542 |
$24K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
518 |
362 |
$24K |
| J0131 |
Injection, acetaminophen, not otherwise specified,10 mg |
1,014 |
976 |
$23K |
| 87081 |
|
3,636 |
3,572 |
$23K |
| 82728 |
|
2,675 |
2,500 |
$22K |
| 82550 |
|
4,418 |
3,416 |
$22K |
| 73560 |
|
1,249 |
1,182 |
$22K |
| A9552 |
Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries |
112 |
111 |
$22K |
| J1170 |
Injection, hydromorphone, up to 4 mg |
2,187 |
1,747 |
$21K |
| 93225 |
|
519 |
502 |
$21K |
| 84439 |
|
3,170 |
3,061 |
$20K |
| 92507 |
Treatment of speech, language, voice, communication, and/or auditory processing disorder |
366 |
188 |
$20K |
| 70551 |
Magnetic resonance imaging, brain; without contrast material |
54 |
54 |
$19K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
2,806 |
2,768 |
$19K |
| 84466 |
|
2,602 |
2,535 |
$19K |
| 82948 |
|
5,640 |
3,066 |
$18K |
| J1642 |
Injection, heparin sodium, (heparin lock flush), per 10 units |
3,334 |
1,329 |
$18K |
| 73140 |
|
937 |
918 |
$16K |
| 86140 |
|
6,647 |
4,490 |
$16K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
2,729 |
2,162 |
$15K |
| 82746 |
|
1,776 |
1,753 |
$15K |
| 83970 |
|
638 |
637 |
$15K |
| J2060 |
Injection, lorazepam, 2 mg |
2,529 |
2,051 |
$14K |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
2,620 |
2,346 |
$14K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
1,094 |
1,090 |
$14K |
| J2704 |
Injection, propofol, 10 mg |
1,712 |
1,637 |
$14K |
| 76857 |
|
314 |
312 |
$14K |
| 94729 |
|
305 |
300 |
$13K |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
1,762 |
1,616 |
$13K |
| 82495 |
|
697 |
681 |
$13K |
| 99232 |
Subsequent hospital care, per day, moderate complexity |
659 |
271 |
$13K |
| 94060 |
|
320 |
316 |
$13K |
| 94664 |
|
586 |
454 |
$13K |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
2,593 |
2,141 |
$13K |
| J1815 |
Injection, insulin, per 5 units |
1,419 |
642 |
$13K |
| 85007 |
|
6,494 |
4,817 |
$12K |
| 82553 |
|
684 |
589 |
$12K |
| 59409 |
Vaginal delivery only (with or without episiotomy and/or forceps) |
25 |
24 |
$12K |
| 83540 |
|
3,331 |
3,238 |
$12K |
| 94726 |
|
297 |
292 |
$12K |
| 0001A |
|
294 |
294 |
$12K |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
2,241 |
1,549 |
$11K |
| J3475 |
Injection, magnesium sulfate, per 500 mg |
1,466 |
985 |
$11K |
| 0683 |
|
80 |
80 |
$11K |
| 87400 |
|
1,123 |
1,086 |
$10K |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
1,655 |
1,571 |
$9K |
| 82140 |
|
2,350 |
1,208 |
$9K |
| 72072 |
|
271 |
266 |
$9K |
| 12001 |
|
276 |
275 |
$9K |
| 87430 |
|
769 |
758 |
$9K |
| 0710 |
|
248 |
244 |
$9K |
| 97799 |
|
387 |
65 |
$9K |
| 85379 |
|
1,042 |
872 |
$9K |
| 73700 |
|
57 |
56 |
$9K |
| 87147 |
|
1,501 |
1,452 |
$8K |
| 94644 |
|
448 |
425 |
$8K |
| 86592 |
|
2,795 |
2,711 |
$8K |
| 84550 |
|
1,923 |
1,645 |
$8K |
| 73552 |
|
252 |
248 |
$7K |
| J0690 |
Injection, cefazolin sodium, 500 mg |
931 |
789 |
$7K |
| 72128 |
|
49 |
49 |
$7K |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
1,387 |
1,289 |
$7K |
| 01961 |
|
25 |
25 |
$7K |
| J0780 |
Injection, prochlorperazine, up to 10 mg |
669 |
617 |
$7K |
| 87631 |
|
112 |
106 |
$7K |
| 82247 |
|
2,420 |
1,474 |
$7K |
| 73120 |
|
316 |
308 |
$6K |
| 93242 |
|
414 |
413 |
$6K |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
614 |
588 |
$6K |
| 82010 |
|
1,065 |
954 |
$6K |
| 0259 |
|
1,517 |
523 |
$6K |
| 72070 |
|
201 |
199 |
$6K |
| 72050 |
|
167 |
166 |
$6K |
| 87210 |
|
1,108 |
1,086 |
$6K |
| 82607 |
|
968 |
948 |
$6K |
| 10060 |
|
218 |
209 |
$6K |
| 84425 |
|
313 |
313 |
$6K |
| J2550 |
Injection, promethazine hcl, up to 50 mg |
791 |
719 |
$6K |
| J1453 |
Injection, fosaprepitant, 1 mg |
42 |
26 |
$6K |
| 99253 |
|
114 |
110 |
$5K |
| 99152 |
|
148 |
140 |
$5K |
| 83615 |
|
1,391 |
1,096 |
$5K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
260 |
256 |
$5K |
| 97010 |
|
482 |
230 |
$5K |
| 72141 |
|
12 |
12 |
$5K |
| 84153 |
|
479 |
470 |
$5K |
| 85652 |
|
3,003 |
2,681 |
$5K |
| 84436 |
|
829 |
813 |
$5K |
| 86780 |
|
687 |
676 |
$5K |
| J1953 |
Injection, levetiracetam, 10 mg |
283 |
240 |
$5K |
| 12011 |
|
74 |
74 |
$4K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
111 |
108 |
$4K |
| 59514 |
|
14 |
14 |
$4K |
| 86803 |
|
451 |
448 |
$4K |
| 73221 |
|
12 |
12 |
$4K |
| 0636 |
|
374 |
332 |
$4K |
| 73620 |
|
212 |
206 |
$4K |
| 77300 |
|
13 |
13 |
$4K |
| 29125 |
|
334 |
327 |
$4K |
| A4344 |
Indwelling catheter, foley type, two-way, all silicone or polyurethane, each |
328 |
314 |
$4K |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
819 |
795 |
$4K |
| 84100 |
|
4,412 |
1,574 |
$4K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
816 |
756 |
$4K |
| C1713 |
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) |
14 |
13 |
$4K |
| A9500 |
Technetium tc-99m sestamibi, diagnostic, per study dose |
31 |
29 |
$4K |
| 0011A |
|
87 |
87 |
$3K |
| 0760 |
|
130 |
111 |
$3K |
| J1644 |
Injection, heparin sodium, per 1000 units |
626 |
224 |
$3K |
| 96402 |
|
46 |
40 |
$3K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
63 |
61 |
$3K |
| 87088 |
|
1,072 |
1,053 |
$3K |
| 73600 |
|
75 |
70 |
$3K |
| 87340 |
|
599 |
591 |
$3K |
| 99222 |
Initial hospital care, per day, moderate complexity |
92 |
91 |
$3K |
| 82435 |
|
1,471 |
1,424 |
$3K |
| J0185 |
Injection, aprepitant, 1 mg |
21 |
12 |
$3K |
| J7050 |
Infusion, normal saline solution, 250 cc |
662 |
473 |
$3K |
| J0330 |
Injection, succinylcholine chloride, up to 20 mg |
248 |
246 |
$3K |
| 73100 |
|
137 |
129 |
$3K |
| 80074 |
|
251 |
242 |
$3K |
| 0002A |
|
70 |
70 |
$3K |
| 70498 |
|
39 |
39 |
$3K |
| 12002 |
|
87 |
87 |
$3K |
| 96417 |
|
167 |
79 |
$3K |
| 99254 |
|
41 |
40 |
$3K |
| 93270 |
|
72 |
72 |
$3K |
| J3486 |
Injection, ziprasidone mesylate, 10 mg |
66 |
36 |
$3K |
| 86141 |
|
225 |
214 |
$3K |
| 94799 |
|
135 |
128 |
$2K |
| 87070 |
|
939 |
815 |
$2K |
| 80202 |
|
959 |
534 |
$2K |
| 73060 |
|
90 |
90 |
$2K |
| 0258 |
|
230 |
125 |
$2K |
| 87420 |
|
234 |
227 |
$2K |
| 99223 |
Prolong inpt eval add15 m |
134 |
130 |
$2K |
| 87205 |
|
1,310 |
1,083 |
$2K |
| 99499 |
|
39 |
27 |
$2K |
| A9575 |
Injection, gadoterate meglumine, 0.1 ml |
433 |
427 |
$2K |
| 72170 |
|
100 |
100 |
$2K |
| 88311 |
|
522 |
505 |
$2K |
| 87220 |
|
289 |
283 |
$2K |
| J0665 |
Injection, bupivicaine, not otherwise specified, 0.5 mg |
248 |
225 |
$2K |
| 80069 |
|
957 |
412 |
$2K |
| 82947 |
|
896 |
861 |
$2K |
| 93925 |
|
26 |
26 |
$2K |
| 82800 |
|
176 |
152 |
$2K |
| 64445 |
|
24 |
24 |
$2K |
| 85651 |
|
491 |
460 |
$2K |
| 82652 |
|
48 |
48 |
$2K |
| 82043 |
|
524 |
521 |
$2K |
| 88313 |
|
34 |
34 |
$2K |
| X3908 |
|
48 |
13 |
$1K |
| 86762 |
|
246 |
238 |
$1K |
| J3370 |
Injection, vancomycin hcl, 500 mg |
112 |
105 |
$1K |
| 30140 |
|
12 |
12 |
$1K |
| 97124 |
|
135 |
88 |
$1K |
| 82570 |
|
840 |
745 |
$1K |
| A9579 |
Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml |
44 |
43 |
$1K |
| 84481 |
|
135 |
135 |
$1K |
| 86923 |
|
194 |
167 |
$1K |
| 81513 |
|
12 |
12 |
$1K |
| 94150 |
|
106 |
88 |
$1K |
| 87149 |
|
50 |
50 |
$1K |
| 27447 |
|
13 |
12 |
$1K |
| 86038 |
|
137 |
137 |
$1K |
| J1630 |
Injection, haloperidol, up to 5 mg |
323 |
280 |
$1K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
25 |
25 |
$1K |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
2,880 |
2,598 |
$994.57 |
| X3910 |
|
48 |
13 |
$905.28 |
| 88302 |
|
50 |
43 |
$901.67 |
| 87522 |
Neg quan hep c or qual rna |
29 |
29 |
$891.18 |
| 73070 |
|
38 |
36 |
$860.71 |
| 84630 |
|
87 |
87 |
$859.04 |
| 73660 |
|
43 |
41 |
$797.34 |
| 36600 |
|
201 |
196 |
$786.36 |
| 85520 |
|
348 |
148 |
$771.73 |
| 84403 |
|
42 |
41 |
$767.40 |
| 64447 |
|
29 |
29 |
$763.75 |
| 97150 |
Therapeutic procedure(s), group (2 or more individuals) |
263 |
96 |
$744.80 |
| J7999 |
Compounded drug, not otherwise classified |
26 |
25 |
$722.28 |
| 97164 |
|
57 |
53 |
$703.37 |
| 82248 |
|
276 |
177 |
$692.21 |
| 88312 |
|
29 |
29 |
$655.44 |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
14 |
14 |
$650.94 |
| 83631 |
|
30 |
27 |
$619.73 |
| J1171 |
Injection, hydromorphone, 0.1 mg |
13 |
12 |
$617.31 |
| 82378 |
|
19 |
12 |
$608.79 |
| 74022 |
|
13 |
12 |
$566.77 |
| 73000 |
|
28 |
25 |
$542.79 |
| 93356 |
|
33 |
33 |
$537.72 |
| 72120 |
|
14 |
14 |
$537.29 |
| 82150 |
|
163 |
133 |
$485.11 |
| J7512 |
Prednisone, immediate release or delayed release, oral, 1 mg |
567 |
533 |
$482.03 |
| 86300 |
|
25 |
24 |
$462.50 |
| J0561 |
Injection, penicillin g benzathine, 100,000 units |
13 |
12 |
$439.78 |
| 84156 |
|
422 |
350 |
$418.75 |
| J2003 |
Injection, lidocaine hydrochloride, 1 mg |
43 |
41 |
$415.66 |
| 70496 |
|
12 |
12 |
$397.93 |
| J2919 |
Injection, methylprednisolone sodium succinate, 5 mg |
30 |
29 |
$397.67 |
| 83525 |
|
41 |
41 |
$395.22 |
| 86077 |
|
18 |
14 |
$388.35 |
| J7060 |
5% dextrose/water (500 ml = 1 unit) |
84 |
37 |
$387.99 |
| 86431 |
|
98 |
98 |
$381.17 |
| J8540 |
Dexamethasone, oral, 0.25 mg |
2,024 |
1,653 |
$369.60 |
| 31500 |
|
14 |
12 |
$355.20 |
| 86481 |
|
25 |
25 |
$349.00 |
| 88112 |
|
30 |
25 |
$342.88 |
| J0736 |
Injection, clindamycin phosphate, 300 mg |
32 |
30 |
$328.00 |
| 87481 |
|
12 |
12 |
$308.70 |
| 86880 |
|
312 |
310 |
$301.62 |
| 88142 |
|
18 |
17 |
$299.40 |
| 87075 |
|
171 |
158 |
$288.98 |
| 87493 |
|
45 |
43 |
$252.12 |
| 96415 |
|
13 |
12 |
$242.28 |
| 86708 |
|
31 |
31 |
$227.85 |
| S0164 |
Injection, pantoprazole sodium, 40 mg |
17 |
13 |
$199.30 |
| 80306 |
|
98 |
92 |
$198.23 |
| 97039 |
|
37 |
25 |
$176.96 |
| 82950 |
|
68 |
68 |
$166.21 |
| 82784 |
|
13 |
12 |
$160.44 |
| 85045 |
|
70 |
66 |
$148.56 |
| 99001 |
|
822 |
720 |
$137.20 |
| S0020 |
Injection, bupivicaine hydrochloride, 30 ml |
14 |
14 |
$133.54 |
| 84300 |
|
150 |
138 |
$125.35 |
| 86308 |
|
33 |
33 |
$117.42 |
| 82533 |
|
40 |
37 |
$116.00 |
| J0571 |
Buprenorphine, oral, 1 mg |
24 |
12 |
$110.33 |
| 85384 |
|
71 |
55 |
$108.63 |
| 76882 |
|
16 |
14 |
$108.34 |
| 89051 |
|
28 |
24 |
$101.14 |
| 88300 |
|
25 |
25 |
$98.77 |
| 87807 |
|
12 |
12 |
$86.72 |
| 84133 |
|
109 |
100 |
$81.43 |
| 82274 |
|
28 |
27 |
$79.24 |
| J1940 |
Injection, furosemide, up to 20 mg |
15 |
12 |
$79.06 |
| Q0163 |
Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen |
59 |
54 |
$72.95 |
| 85014 |
|
118 |
94 |
$68.46 |
| 80051 |
|
13 |
13 |
$55.37 |
| 36591 |
|
236 |
131 |
$52.50 |
| 84165 |
|
14 |
14 |
$49.59 |
| 86709 |
|
12 |
12 |
$41.42 |
| J8597 |
Antiemetic drug, oral, not otherwise specified |
30 |
25 |
$38.69 |
| 85018 |
|
91 |
75 |
$37.16 |
| 83721 |
|
15 |
14 |
$23.28 |
| 87045 |
|
13 |
13 |
$20.41 |
| 87076 |
|
13 |
13 |
$18.72 |
| 87046 |
|
13 |
13 |
$6.76 |
| 84155 |
|
13 |
13 |
$3.53 |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
151 |
150 |
$0.01 |
| 0637R |
|
2,434 |
1,605 |
$0.00 |
| 0259R |
|
1,485 |
938 |
$0.00 |
| 80320 |
|
49 |
43 |
$0.00 |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
106 |
88 |
$0.00 |
| 96376 |
|
104 |
100 |
$0.00 |
| 97162 |
|
26 |
26 |
$0.00 |
| 0370 |
|
13 |
12 |
$0.00 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
15 |
15 |
$0.00 |
| 84112 |
|
58 |
55 |
$0.00 |
| J7614 |
Levalbuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 0.5 mg |
32 |
27 |
$0.00 |